Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Open accessThe DOI matches its Crossref record; 194 of the 196 references it cites were found in a registry or an index.
Abstract
Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment of atherosclerosis is focused on limiting its risk factors, such as hyperlipidemia or hypertension. However, treatment targeting the inflammatory nature of atherosclerosis is still very limited and deserves further attention to fight atherosclerosis successfully. Here, we review the current development of inflammation and atherosclerosis to discuss novel insights and potential targets in atherosclerosis, and to address drug discovery based on anti-inflammatory strategy in atherosclerotic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Anti-inflammatory drugs such as Canakinumab, an IL-1β monoclonal antibody, have been demonstrated to have effectiveness independent from lipid-lowering on reducing cardiovascular events in patients with coronary artery disease.7,8”
From The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Abe, Y., Kawakami, A., Osaka, M., Uematsu, S., Akira, S., Shimokado, K., Sacks, F. M., & Yoshida, M. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.210427 · Cited by 29
RetractedMonocyte Chemoattractant Protein-1 (MCP-1): An Overview
Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0027 · Cited by 3,889 · cited 1×
“Both CCL2 and its receptor C-C motif chemokine receptor-2 (CCR2) have been demonstrated to be involved in various diseases, including atherosclerotic cardiovascular disease [153].”
BackgroundStewart, C. R., Stuart, L. M., Wilkinson, K., van Gils, J. M., Deng, J., Halle, A., Rayner, K. J., Boyer, L., Zhong, R., Frazier, W. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1836 · Cited by 1,513
Van Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
(2012) · The Lancet · doi:10.1016/s0140-6736(12)60110-x · Cited by 1,146 · cited 2×
“Targeting treatment of IL-6 receptor (IL-6R) also provided a promising therapeutic approach to prevention of coronary heart disease [66].”
BackgroundNatural regulatory T cells control the development of atherosclerosis in mice
Ait-Oufella, H., Salomon, B. L., Potteaux, S., Robertson, A.-K. L., Gourdy, P., Zoll, J., Merval, R., Esposito, B., Cohen, J. L., Fisson, S., et al. (2006) · Nature Medicine · doi:10.1038/nm1343 · Cited by 1,100
Ridker, P. M. (2016) · Circulation Research · doi:10.1161/circresaha.115.306656 · Cited by 1,002 · cited 1×
“However, the inhibition of IL-1β does not adversely affect lipid levels [54].”
BackgroundMackay, F., & Schneider, P. (2009) · Nature Reviews Immunology · doi:10.1038/nri2572 · Cited by 930 · cited 1×
“BAFF-R is expressed on mature B-cells and binds BAFF that is crucial survival factor for maturation and survival of B2 cells [104].”
BackgroundT-cell regulation by CD28 and CTLA-4
Alegre, M.-L., Frauwirth, K. A., & Thompson, C. B. (2001) · Nature Reviews Immunology · doi:10.1038/35105024 · Cited by 914 · cited 1×
“However, LDLrCD80CD86 mice have twofold increase of atherosclerotic lesion [125].”
BackgroundReduction of atherosclerosis in mice by inhibition of CD40 signalling
Mach, F., Schönbeck, U., Sukhova, G. K., Atkinson, E., & Libby, P. (1998) · Nature · doi:10.1038/28204 · Cited by 910
Research works printed but not linked: 1
- [171]Bonnefont-Rousselot D. Lp-PLA, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques. Ann. Pharm. Fr. 2016 74 190 197 26499399
Cited by
Duan, H., Zhang, Q., Liu, J., Li, R., Wang, D., Peng, W., & Wu, C. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105599 · Cited by 255
Beverly, J. K., & Budoff, M. J. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.12970 · Cited by 214
“Helper T (TH) cells have multiple subtypes; most notably, TH1 cells are clearly atherogenic, whereas regulatory T cells (Tregs) are atheroprotective; the other subtypes do not yet have clearly defined roles.(11) The protein component of the LDL particle is presented by macrophages and dendritic cells to COMMENTARY 103”
BackgroundInfluentialUnveiling the Role of Inflammation and Oxidative Stress on Age-Related Cardiovascular Diseases
de Almeida, A. J. P. O., de Almeida Rezende, M. S., Dantas, S. H., de Lima Silva, S., de Oliveira, J. C. P. L., de Lourdes Assunção Araújo de Azevedo, F., Alves, R. M. F. R., de Menezes, G. M. S., dos Santos, P. F., Gonçalves, T. A. F., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1954398 · Cited by 162
“The process to formation of atherosclerosis involves damage in vascular endothelial cells through oxidative stress, cytokines, and chemokines [193, 194].”
BackgroundHuang, J., Zhang, Q., Wang, R., Ji, H., Chen, Y., Quan, X., & Zhang, C. (2019) · Medical Science Monitor · doi:10.12659/msm.919802 · Cited by 164
“Results from previous experimental and clinical research suggested that patients with elevated SII had greater risk of poor clinical outcomes [32].”
ResultVitamin D and Its Role in the Lipid Metabolism and the Development of Atherosclerosis
Surdu, A. M., Stănoiu-Pînzariu, O., Ciobanu, D. M., Negru, A. G., Cainap, S. S., Lazea, C., Iacob, D., Săraci, G., Tirinescu, D. C., Borda, I. M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9020172 · Cited by 205
“Modulating the immune and inflammatory response in atherogenesis could provide potential future clinical benefits besides the classical lipid-lowering approach [66].”
Background
Metadata
- Authors
- Li, B., Li, W., Li, X., & Zhou, H.
- Affiliations
- Army Medical University (CN)
- Chongqing Medical University (CN)
- Corresponding author
- Zhou, Hong
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2017-04-12
- Volume
- 23
- Issue
- 8
- Pages
- 1216-1227
- ISSN
- 1381-6128 (ISSN-L)
- PMC
- PMC6302344
- OpenAlex
- W2572385011
- Semantic Scholar
- 0e839dc181b1a7907ef1197fe2d5012d3a58a7d1
- Cited by
- 130
- References
- 196
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 31 · 2021: 34 · 2020: 18 · 2019: 10 · 2018: 2 · 2017: 1
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Current Pharmaceutical Design (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- atherosclerosis, inflammation, anti-inflammatory therapy, therapeutic target, drug discovery, low-grade inflammation, arterial wall, hyperlipidemia, hypertension
- MeSH terms
- Animals, Anti-Inflammatory Agents, Humans, Inflammation, Atherosclerosis, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis. https://app.cochat.ai/papers/10.2174/1381612822666161230142931
- The paper
- Li, B., Li, W., Li, X., & Zhou, H. (2017). Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis. Current Pharmaceutical Design. https://doi.org/10.2174/1381612822666161230142931
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.